Ophthalmic suspension composition

A method of treating an ophthalmic inflammatory condition comprising administering to an eye of a patient in need of said treating a suspension comprising an ophthalmic anti-inflammatory active ingredient suspended in a formulation vehicle, wherein the ophthalmic anti-inflammatory active ingredient is present as milled particles that have Dv50<1 μm, and the formulation vehicle comprises a suspending agent comprising a carboxyvinyl polymer and a particle size stabilizing agent comprising a non-ionic cellulose derivative, wherein the non-ionic cellulose derivative is hydroxypropylmethyl cellulose, the carboxyvinyl polymer is polycarbophil, the ophthalmic active ingredient is loteprednol etabonate, and the suspension comprises loteprednol etabonate at about 0.38 wt %, polycarbophil at 0.1-0.5 wt %, and hydroxypropylmethyl cellulose at 0.1-0.5 wt %.